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SUMMARY
We created a mouse model in which E-cadherin in the
pancreas was specifically deleted. Loss of E-cadherin resul-
ted in pancreatitis-like changes under physiological condi-
tions and contributed to carcinogenesis in the presence of an
oncogene.
BACKGROUND & AIMS: E-cadherin (Cdh1) is a key molecule
for adherence required for maintenance of structural homeo-
stasis. Loss of E-cadherin leads to poor prognosis and the
development of resistance to chemotherapy in pancreatic can-
cer. Here, we evaluated the physiological and pathologic roles
of E-cadherin in the pancreas.
METHODS: We crossbred Ptf1a-Cre mice with Cdh1f/f mice to
examine the physiological roles of E-cadherin in the pancreas.
In addition, we crossbred these mice with LSL-KrasG12D/þ mice
(PKC) to investigate the pathologic roles of E-cadherin. We also
generated a tamoxifen-inducible system (Ptf1a-CreERT model).
Organoids derived from these models using lentiviral trans-
duction were analyzed for immunohistochemical features.
Established cell lines from these organoids were analyzed for
migratory and invasive activities as well as gene expression by
complementary DNA microarray analyses.
RESULTS: None of the Ptf1a-Cre mice crossbred with Cdh1f/f
mice survived for more than 28 days. We observed aberrant
epithelial tubules that resembled the structure of acinar-to-
ductal metaplasia after postnatal day 6, showing features of
pancreatitis. All of the PKC mice died within 10 days.
We observed tumorigenicity with increasing stroma-like
aggressive tumors. Ptf1a-CreERT models showed that deletion
of E-cadherin led to earlier pancreatic intraepithelial neoplasm
formation. Cells established from PKC organoids had greater
migratory and invasive activities, and these allograft tumors
showed a poorly differentiated phenotype. Gene expression
analysis indicated that Hdac1 was up-regulated in PKC cell lines
and a histone deacetylase 1 inhibitor suppressed PKC cell
proliferation.
CONCLUSIONS: Under physiological conditions, E-cadherin is
important for maintaining the tissue homeostasis of the
pancreas. Under pathologic conditions with mutational Kras
activation, E-cadherin plays an important role in tumor
formation via the acquisition of tumorigenic activity. (Cell
Mol Gastroenterol Hepatol 2020;9:105–119; https://doi.org/
10.1016/j.jcmgh.2019.09.001)
Keywords: Pancreas; Oncogene; Gene Regulation; Pancreatic
Cancer; E-Cadherin.
E-cadherin is a Ca2þ-dependent adhesion proteinbelonging to the classic cadherin family. Physiologi-
cally, the classic cadherins play important roles in cell-to-cell
adhesion and epithelial polarity. Although E-cadherin is one
of the constituent members of adherens junctions, it also is
responsible for intracellular signaling and gene transcription.1,2
E-cadherin knockout mice die at an early embryonic
stage and, therefore, conditional knockout mice have been
used in studies. For example, deletion of E-cadherin in skin
impaired epidermal barrier function, resulting in death at
the neonatal stage.3 We reported previously that deletion of
E-cadherin in the liver leads to the development of peri-
portal inflammation resembling sclerosing cholangitis via
impairment of the intrahepatic biliary network.4 Therefore,
E-cadherin plays an important role in tissue homeostasis,
although its roles differ among organs.
With regard to the pancreas, previous studies have indicated
that E-cadherin expression was up-regulated in rodent models
of chemically induced acute pancreatitis. This reaction was
considered to be a response to protect and repair cell–cell ad-
hesions of pancreatic acinar cells.5,6 On the other hand, chronic
pancreatitis, which is associated with a high risk of pancreatic
adenocarcinoma (PDAC), showed low or no expression of E-
cadherin.7 However, the precise functional role of E-cadherin in
the pancreas still is unknown, especially in vivo.
It has been reported that alteration of E-cadherin expres-
sion contributes to cancer progression.4 In human
gastric cancer, loss of E-cadherin has been linked with
diffuse-type cancer,8 and germline-inactivating mutations in
the E-cadherin gene are characteristic of hereditary diffuse
gastric cancer syndrome.9 Loss of E-cadherin has organ-
specific effects (eg, liver, stomach, skin, or mammary gland),
such as inflammation, hyperproliferation, and promotion of
tumor formation.4,10–12 In pathogenic states, E-cadherin has
been reported as a marker of morphologic changes, such as
epithelial–mesenchymal transition (EMT), but there is little
evidence that cancers undergo EMT by deletion of E-cadherin.
Pancreatic cancer is the third leading cause of cancer-related
deaths, with a 5-year relative survival rate of 8%. The majority
of patients are diagnosed at an advanced stage, for which
the 5-year survival rate is 3%.13 Reduction of E-cadherin
expression in pancreatic cancer is observed especially in un-
differentiated cancers and is correlatedwith EMT induction and
poor prognosis.14 Transcriptional repressors, such as Snail,
Slug, and Twist, play important roles in induction of EMT, and
E-cadherin is a major target of these factors. However, it is
unclear whether the loss of E-cadherin is a real regulator of
EMT induction and pancreatic cancer development.15
Therefore, we investigated the roles of E-cadherin in the
pancreas and pancreatic tumor development using
pancreas-specific E-cadherin knockout mice.
Results
Cdh1 Is Required for Growth and Maintenance of
the Pancreas
To examine the physiological roles of E-cadherin in the
pancreas, we crossbred homozygous loxP-flanked alleles
of Cdh1 (Cdh1f/f) mice with pancreas transcription factor
1a (Ptf1a)-Cre transgenic mice expressing Cre recombinase
from the Ptf1a promoter (Ptf1a-Cre; Cdh1f/þ). Cdh1 het-
erodeficiency did not contribute to the phenotype. Next,
we crossbred Ptf1a-Cre; Cdh1f/þ with Cdh1f/f mice to
generate Ptf1a-Cre; Cdh1f/f mice (named PC mice)
(Figure 1A). Successful Cre-mediated recombination was
assessed by polymerase chain reaction (PCR). PC mice
were born at the expected Mendelian ratio with a
morphologically normal pancreas. During postnatal day
0 (P0) to P2, there were no differences in appearance or
histology between Cdh1f/f and PC mice (Figure 1B). How-
ever, PC mice remained small compared with the controls
after P3–P4 (Figure 1C). PC mice began to die at P12, and
none of the PC mice survived for more than 28 days. The
pancreatic histology of PC mice changed markedly at
P6–P15. We observed dilated abnormal acinar cells at P6,
and aberrant epithelial tubules structurally resembling
acinar-to-ductal metaplasia (ADM) (Figure 1B). There was
no E-cadherin expression on the surface of pancreatic
acinar cells, whereas E-cadherin–positive cells were
observed in ADMs (Figure 1D). These results suggested
that E-cadherin was not required for pancreatic develop-
ment at the embryonic stage but was required for growth
and maintenance of the pancreas in the postnatal stage.
Loss of Cdh1 Causes Inflammatory and Fibrotic
Changes
We performed immunohistochemistry (IHC) analyses to
examine the roles of E-cadherin in the morphologic changes
seen in the pancreas of PC. PC mice had significantly
decreased numbers of amylase-positive cells and increased
numbers of cytokeratin 19 (CK19)-positive cells, as well as
histologic changes reflected by a reduced area of acini and
an increased number of ductal-like structures (Figure 2A
and B). The serum amylase level was increased at P6, but
decreased at P12, compared with controls, which showed no
such changes (Figure 2G). These results also were consistent
with the results regarding messenger RNA (mRNA) levels
(Figure 2I). At P12–P15, intact areas of acini had almost
disappeared, and remaining areas had been replaced by a-
smooth muscle actin (a-SMA)-positive fibrotic cells as well
Abbreviations used in this paper: ADM, acinar-to-ductal metaplasia;
a-SMA, a-smooth muscle actin; cDNA, complementary DNA; CK19,
cytokeratin 19; DMEM, Dulbecco’s modified Eagle medium; EMT,
epithelial–mesenchymal transition; gH2AX, g histone 2AX; HDAC,
histone deacetylase; IHC, immunohistochemistry; Klf, Krüppel-like
factor; mRNA, messenger RNA; P, postnatal day; PanIN, pancreatic
intraepithelial neoplasm; PC, Ptf1a-Cre; Cdh1f/f; PCR, polymerase
chain reaction; PDAC, pancreatic ductal adenocarcinoma; p-ERK,
phospho–extracellular signal-regulated kinase; PK, Ptf1a-Cre; LSL-
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as ADMs. Areas with positive Picro-Sirius red (PSR) staining
appeared in the stroma, indicating the presence of collagen
fibers (Figure 2C and D).
Cells positive for CD45, a marker of leukocyte common
antigen, increased over time in the stroma (Figure 2E
and H). In addition, relative mRNA expression levels of in-
flammatory cytokines and chemokines, such as Cxcl2, Ccl2,
interleukin 6, and tumor necrosis factor a, were increased at
P8 (Figure 2I). Cleaved caspase-3–positive cells, a marker of
apoptosis, were nonspecifically observed with Cdh1f/f acinar
cells, but PC at P6–12 showed strong staining around ductal
structures, indicating apoptosis at the sites of ADM forma-
tion (Figure 2F). At P15, pancreatic tissue of PC had been
almost completely replaced with fibrotic tissue, and cleaved
caspase-3 staining in these areas was not clear; all PC
mice died by P28 because their pancreas had been func-
tionally compromised by the lack of E-cadherin. These re-
sults indicated that loss of E-cadherin in the pancreas
caused pancreatitis-like changes accompanied by ADM-like
changes. However, we did not observe pancreatic intra-
epithelial neoplasia (PanIN), a precursor of PDAC. We
quantified the area positive for amylase, cleaved caspase 3,
CK19, a-SMA, and PSR in the P6 and P15 pancreas
(Figure 2J).
Loss of E-Cadherin Provides Tumorigenic
Activity to Pancreatic Cells and Contributes to
Carcinogenesis
The mutational activation of Kras is the most
common genetic mutation in PDAC.16 To investigate
further the pathologic roles of E-cadherin in the
pancreas, we cross-bred mice with the Ptf1a-Cre, LSL-
KrasG12D/þ, and Cdh1f/f alleles to generate mice with a
combination of oncogenic KrasG12D/þ expression and
Cdh1 deletion in the pancreas. Previous studies indicated
that the Ptf1a-Cre; LSL-KrasG12D/þ (PK) mouse model
started to develop PanIN from 2 weeks of age, and some
eventually developed PDAC.17,18 We also confirmed that
the PK mouse pancreas showed no morphologic changes
during P0–P8 (Figure 3A). In contrast, when Cdh1 deficiency
was added to KrasG12D/þ (Ptf1a-Cre; LSL-KrasG12D/þ;
Cdh1f/f [PKC] mice), ADMs and PanINs (low-grade PanIN or
PanIN1A/B) were observed at P4–P5, whereas no abnormal
changes were observed at P0–P2. The P8 PKC mouse
pancreas showed aberrant and dilated ducts corresponding
to PanIN-2/3 and desmoplastic reaction-like changes
(Figure 3A). PanINs of PKC mice showed partial staining by
IHC for E-cadherin at P4–P5. At P7–P8, PanINs of PKC mice
also showed partial positive staining for E-cadherin and
some showed structural abnormalities, while other lesions
in the pancreas showed no staining for E-cadherin
(Figure 3B). Decreased amylase staining and increased CK19
staining were observed, as observed in PC mice (Figure 3C
andD). At P7–P8, the hard pancreas of PKCmice invaded and
adhered to the intestine, andmice died with massive ascites.
However, we did not observe anymetastasis in other organs.
The P4 PKC mouse pancreas contained abundant stromal
components that showed positive staining for a-SMA and
vimentin (Figure 3E).
To characterize these components, we crossbred PKC
mice with Rosa26-LSL-tdTomato. Ptf1a-Cre recombinant
cells were labeled with td Tomato and confirmed by staining
with red fluorescent protein (RFP). All PanINs and
Figure 1. E-cadherin maintains pancreatic homeostasis. (A) Experimental protocol for deleting E-cadherin in the pancreas.
(togoTV mouse images was used) (B) H&E staining of the pancreas obtained from Cdh1f/f and PC mice on P0–P15. (C) Gross
images of Cdh1f/f and PC mice on P8. (D) Immunohistochemical analysis of E-cadherin in the pancreas from mice of each
genotype and time point. Upper panels: Cre-negative mice (Cdh1f/f). Lower panels: Cre-positive mice (PC). Scale bars: 100 mm.
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approximately half of the cells in stromal components
were positive for RFP, suggesting that not only PanINs
but also many stromal cells were recombined with
KrasG12D/þ. In addition, these lesions were positive for
Ki67 and phospho–extracellular signal-regulated kinase
(p-ERK). These results indicated that PKC stromal com-
ponents contained tumor cells causing EMT with
aggressive and invasive phenotypes (Figure 4A). We also
performed immunofluorescence staining for RFP and
CD44. Because RFP-positive cells and CD44-positive cells
co-stained with some spindle-shaped cells, some of the
cells undergoing recombination were likely to have had
increased tumorigenic activity (Figure 4B). To investigate
the changes caused by loss of E-cadherin, we evaluated
DNA damage. Staining with g histone 2AX (gH2AX) was
performed to assess DNA double-strand breaks. Although
Figure 2. Genetic inactivation of Cdh1 caused pancreatitis-like changes. IHC analysis of the Cdh1f/f and PC pancreas on
P6–P15 showed staining for (A) amylase, (B) CK19, (C) a-SMA, (D) PSR, (E) CD45, and (F) cleaved caspase-3 in the pancreas
from mice of each genotype. (G) Serum amylase level of mice of each genotype on P6 and P12. (H) Quantification of CD45-
positive cells per high-power field showed an increasing number of CD45-positive cells in the PC pancreas compared with the
Cdh1f/f pancreas. (I) Relative mRNA expression levels of amylase, CK19, inflammatory cytokines, and chemokines from
pancreatic tissues of Cdh1f/f and PC mice on P8. (J) Quantification of the area of positivity for amylase, cleaved caspase-3,
CK19, a-SMA, and PSR at P6 and P15 in the pancreas of PC mice compared with wild-type mice (Cdh1f/f). Scale bar: 100 mm.
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strongly positive nuclei were observed in PC mice, little
staining was observed in PK mice. P4–P5 PKC mice
showed slight positive staining, but the staining weak-
ened at P7–P8 (Figure 4C). Similarly, cleaved caspase-3
was positive in PC, but in PKC the staining became
weak (Figure 4D). ADM and PanIN lesions were mixed in
the pancreas of PKC at P4. ADM lesions were positive for
cleaved caspase-3, while PanIN lesions were negative
(Figure 4E). To assess the extent of DNA damage, we
quantified by IHC the proportions of cells positive for
cleaved caspase-3 and gH2AX (Figure 4F). Chemotherapy
and radiotherapy are mainly responsible for DNA dam-
age, but previous studies have shown that cells
expressing oncogenic KrasG12D/þ acquired resistance
through stem cell conversion.19 When pancreatic tissues
of PKC were evaluated by quantitative reverse-
transcription PCR, the levels of Cd44, Krüppel-like fac-
tor 4 (Klf)4, Klf5, and Cd133 mRNA expression as markers
of stem cells were increased compared with wild-type
(Figure 4G). Cells positive for CD44, KLF4, and KLF5 on
IHC were seen in the PKC pancreas, especially PanIN
lesions (Figure 4H). These observations suggested that
loss of E-cadherin provided tumorigenic activity to
pancreatic cells and contributed to PanIN formation.
Establishment of Pancreatic Organoids From
Cdh1 Knockout Mice
To elucidate further the molecular mechanisms un-
derlying the functions of E-cadherin, we established
organoids derived from the pancreas of Cre-negative
Cdh1f/f, LSL-KrasG12D/þ, LSL-KrasG12D/þ; Cdh1f/f mice, and
induced Cre-recombination using lentivirus (see the
Materials and Methods section) (corresponding to PC, PK,
and PKC organoids, respectively). Loss of E-cadherin and
expression of oncogenic KrasG12D/þ were confirmed by
Western blot and IHC (Figure 5A and B). PC organoids
represented the collapsed form, while other organoids
showed a spherical shape. PK and PKC organoids,
expressing oncogenic KrasG12D/þ, had dysplastic tall
columnar cells. PC organoids contained many cleaved
caspase-3–positive cells, whereas PKC showed only partial
positivity for caspase-3. These results were consistent
with the in vivo data. Although loss of E-cadherin caused
Figure 3. Loss of E-cadherin with mutational activation of Kras causes the formation of PanIN structures with des-
moplastic reaction-like changes. (A) H&E staining of the pancreas from PK and PKC mice on P0–P8. IHC analysis of (B) E-
cadherin, (C) amylase, and (D) CK19 in mice of the indicated genotypes and at the indicated time points. (E) The P8 PKC
pancreas showed positive IHC staining for a-SMA and vimentin in stroma.
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disruption of the morphology owing to apoptosis, addition
of oncogenic KrasG12D/þ reversed that effect (Figure 5B).
Cdh1 was re-expressed using lenti-Cdh1 in PKC organoids
(PKCþC). PKCþC organoids showed aligned structures
similar to the original PK organoids (Figure 5C). E-cad-
herin expression was confirmed by Western blot
(Figure 5D). We compared the expression of EMT markers
(Snail and Twist) in PKC and PKCþC RNA samples to
determine whether cadherin was caused by EMT because
the levels of EMT markers did not differ significantly be-
tween the 2 types of samples (Figure 5E). Immunofluo-
rescence analysis showed E-cadherin and b-catenin
costaining in the cell wall in PKCþC. In contrast, b-catenin
staining was observed in the cytoplasm in PKC organoids,
suggesting increased Wnt signaling activity (Figure 5F). To
examine Wnt signaling activity, we evaluated the mRNA
levels of c-Myc, Axin1, and Lef1, which were higher in PKC
compared with PKCþC (Figure 5G).
Figure 4. Loss of E-cadherin with mutational activation of Kras contributed to carcinogenesis. (A) IHC analysis for RFP,
p-ERK, and Ki67 of PKC with td Tomato at P4. Black arrowheads: positive staining cells in stroma. (B) Immunofluorescence for
RFP (red), CD44 (green), and 4’,6-diamidino-2-phenylindole (DAPI) (blue) in the PKC pancreas at P4. IHC analysis of (C) gH2AX
and (D) cleaved caspase-3 from mice of the indicated genotypes and time points. (E) ADM structures showed positive IHC
staining for cleaved caspase-3, whereas PanIN structures in the PKC pancreas at P4 showed mild positivity. (F) Quantification
of the cleaved caspase-3– and gH2AX-positive area in the P0–P2, P4–P5, and P7–P8 pancreas of PC and PKC mice
compared with PKmice. (G) Relative mRNA expression levels of Cd44, Klf4, Klf5, and Cd133 in pancreatic tissues of wild-type
and PKC mice on P8. (H) IHC analysis of CD44, KLF4, and KLF5 from wild-type (WT) and PKC mice. Scale bar: 100 mm.
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Cdh1-Deficient Cell Line With Kras Mutation
Showed Greater Migratory and Invasive Activity
PC, PK, and PKC organoids were transplanted subcuta-
neously into nude mice to evaluate carcinogenesis. After 4
weeks, PK and PKC organoids formed tumors, whereas none
(0 of 4) of the PC organoids formed tumors. E-cadherin–-
positive ductal structures were found in PK tumors but
disappeared in PKC tumors, and PKC tumors had structures
similar to poorly differentiated adenocarcinoma according
to the World Health Organization classification (Figure 6A
and B). Evaluation of mesenchymal cells by IHC for vimentin
showed partial positivity in PK, but extensive positivity in
PKC (Figure 6C). We also examined liver metastasis by
injecting these cells into the spleen. Liver metastases were
induced successfully by both PK and PKC cells, but tumor
number and size did not differ in the cell types. Tumor
histology was consistent with the allograft model, and
ductal structures were found in PK tumors but not in PKC
tumors. We also generated an orthotopic transplant model
in which cells were injected into the pancreas, which had
similar tissue types to the liver metastasis model (Figure 6D
and E). Therefore, 2-dimensional (2D) culture was possible
Figure 5. Establishment of pancreatic organoids expressing each genotype. (A) Confirmation of Cre-recombination using
lentivirus by Western blot. ACTB (beta actin) served as loading control. Cre indicates lentivirusinfection expressing cre
recombinase and Emp indicates control lentivirus infection. (B) H&E and IHC staining for E-cadherin and cleaved caspase-3 in
pancreatic organoids after gene recombination. (C) H&E staining of PKC and PKCþC (Cdh1 re-expressing) organoids. (D)
Confirmation of Cre-recombination and lentivirus-mediated Cdh1 re-expression by Western blot. (E) Relative mRNA levels of
Snail and Twist in PKC and PKCþC organoids. (F) Immunofluorescence staining for b-catenin (red), E-cadherin (green), and
4’,6-diamidino-2-phenylindole (DAPI) (blue) of PKC and PKCþC organoids. (G) Relative mRNA levels of c-Myc, Axin1, and Lef1
in PKC and PKCþC organoids. WT, wild-type.
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for PK and PKC, and we performed functional evaluation.
Comparison of PKC with PK lines showed that loss of
E-cadherin was associated with faster closure in a wound
healing assay (Figure 6F) and greater invasive capability in
an invasion assay (Figure 6G). These results suggested that
loss of E-cadherin significantly accelerates genetically
induced pancreatic tumor formation through induction
of EMT.
Loss of E-Cadherin in the Mature Pancreas
Accelerates PanIN Formation
The mouse model described earlier was not suitable
for long-term analysis of early death. Therefore, we
generated a mouse model using the tamoxifen-inducible
Cre recombination system. Tamoxifen was administered
orally at 6 weeks of age, and the same amount was
administered again 1 week later. Analysis was performed
Figure 6.Cdh1 deletion resulted in mesenchymal features with acquisition of migratory and invasive properties.
Subcutaneous transplants from PK and PKC organoids were evaluated by staining with (A) H&E and for (B) E-cadherin and (C)
vimentin. (D) PKC cells in liver metastases also lacked E-cadherin. IHC analysis of E-cadherin in liver metastatic allografts of
PK and PKC mice. T indicates tumor. (E) H&E staining to confirm orthotopic transplantation of PK and PKC cells. (F) Wound
healing assay showed that PKC cell lines had increased migratory ability compared with PK cell lines on days 2 and 6. (G)
Invasion assay showed staining of greater numbers of PKC cells than PK cells.
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1 and 6 weeks after tamoxifen administration (Figure 7A).
We compared Ptf1a-CreERT; KrasG12D/þ; Cdh1f/f (iKrasG12D/þ;
Cdh1f/f) with Ptf1a-CreERT; KrasG12D/þ; Cdh1f/þ (iKrasG12D/þ;
Cdh1f/þ) because Cdh1 heterodeficiency did not contribute
to the phenotype (Figure 7B). There were no phenotypic
changes in either mouse line at 1 week after tamoxifen
administration. At 6 weeks, PanIN formation and desmo-
plastic reaction were observed in iKrasG12D/þ; Cdh1f/f
(Figure 7B). Acini disappeared in iKrasG12D/þ; Cdh1f/f, and
E-cadherin was positive only in the ductal part
(Figure 7C). Even in these mouse models, the levels of
Cd44 and Klf5 mRNA expression were increased, as in PKC
mice. In addition, the mRNA level of c-Myc was increased
(Figure 7D), which may explain activation of Wnt
signaling and is similar to the results in Figure 5F and G.
The iKrasG12D/þ; Cdh1f/f stroma showed strongly positive
staining for vimentin on IHC (Figure 7E). Next, we
crossbred iKrasG12D/þ; Cdh1f/f mice with
Rosa26-LSL–yellow fluorescent protein (YFP) (iKrasG12D/þ;
Cdh1f/f; Rosa26-YFP) to allow lineage tracing of stromal
cells. In this model, YFP was expressed in cells with
functional Cre-recombinase and confirmed by IHC for
green fluorescent protein staining. When Cre-
recombination was caused by administration of tamox-
ifen, green fluorescent protein–positive cells were
observed in stroma, but the proportion of positive cells
was relatively small compared with cells of PKC mice. It
was considered that the cells expressing Ptf1a had
morphologically changed into spindle-shaped cells (ie,
tumor cells) with EMT (Figure 7F, black arrowheads).
Figure 7. Loss of E-cadherin in the mature pancreas. (A) Protocol of E-cadherin deletion in the pancreas. (togoTV mouse
images was used) (B) H&E staining and (C) IHC analysis for E-cadherin in mice of the indicated genotypes and at various time
points. (D) Relative mRNA expression levels of Cd44, Klf5, and c-Myc in pancreatic tissues from mice of each genotype at 6
weeks after tamoxifen administration. WT, Cre-negative mice, f/þ, iKrasG12D/þ; Cdh1f/þ, f/f, iKrasG12D/þ; Cdh1f/f. (E) IHC
analysis for vimentin showed desmoplastic reaction in the iKrasG12D/þ; Cdh1f/f pancreas, but not in iKrasG12D/þ; Cdh1f/þ at 6
weeks after tamoxifen administration. (F) IHC analysis for green fluorescent protein (GFP) in mice of iKrasG12D/þ; Cdh1f/f;
Rosa26-YFP at 6 weeks after tamoxifen administration. Black arrowheads: positive staining cells in the stroma. W, week; WT,
wild-type.
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Cdh1 Deletion Increases Hdac1 Expression in
PKC Cell Lines
Both PKC and PKCþC were subjected to complementary
DNA (cDNA) microarray analysis. Analysis of the data with
gene set enrichment analysis showed differences (nominal
P < .05) in sets of genes, such as those involved in DNA
damage and chromosome organization (Figure 8A). The top
20 up-regulated genes in PKC compared with PKCþC were
extracted. We focused on Hdac1 (Figure 8B) because histone
deacetylase (HDAC) inhibitors have been reported to be
effective in pancreatic cancer cells.20 To investigate the
contribution of Cdh1 deficiency to its effect, we performed a
proliferation assay using cells grown in 2D culture. PKC cells
had a higher proliferative capacity than PKCþC, but a sig-
nificant growth inhibitory effect of HDAC inhibitor (SAHA)
was observed in PKC cells (Figure 8C). These results suggest
that Hdac1 might be a therapeutic target for cells with
E-cadherin deletion.
Discussion
The results of the present study show the roles of Cdh1
in a pancreas-specific conditional knockout mouse model. In
the physiological state, loss of E-cadherin resulted in the
disappearance of acinar cells and the formation of ducts
with apoptotic changes, suggesting a phenotype of
pancreatitis-like changes based on evaluation of serum
amylase levels, CD45-positive cells, and inflammatory cyto-
kines. Pancreatitis-like changes are caused by the increased
levels of proinflammatory cytokines at P8 and the serum
level of amylase at P6. In contrast, the serum amylase level
and the number of IHC-positive cells were decreased at P12.
In addition, the number of caspase-3, IHC-positive cells was
greater at P15 compared with P6. Therefore, loss of E-cad-
herin causes tissue disruption and induces pancreatitis-like
changes, followed by death at approximately P28 because of
functional failure of the pancreas. In vitro, organoids could
not maintain epithelial alignment, indicating a direction in
which apoptosis was induced as in vivo. Previously, we re-
ported that loss of E-cadherin in the intrahepatic bile duct
epithelium functionally impaired biliary flow, and subse-
quently induced cholestatic liver injury and sclerosing
cholangitis.4 We assumed that E-cadherin plays an impor-
tant role in maintaining cell-to-cell contact in the pancreatic
duct and that loss of E-cadherin impairs the flow of
pancreatic juice and eventually causes pancreatitis-like
changes. Similar mouse data were published during prepa-
ration of this manuscript, although no organoids and human
data have been reported.21 Consistent with previous studies,
even in the pancreas, E-cadherin deficiency alone did not
induce carcinogenesis.4,22,23 Mutational Kras activation was
found in human pancreatic cancer at a frequency of 90%,16
and mutational Kras activation was also an important ge-
netic mutation in a mouse model.24 In the mouse model, the
Figure 8. The presence of Cdh1-regulated Hdac1. (A) Gene set enrichment analysis of expressed genes from cDNA
microarrays of PKC and PKCþC (nominal P value < .05). (B) Expression data of the top 20 genes showing differences in
expression between PKC and PKCþC. (C) Proliferation assay for PKC and PKCþC with or without HDAC inhibitor (SAHA). ad,
addition; DMSO, dimethyl sulfoxide.
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frequency of carcinogenesis induced only by Kras mutation
was low, and the incidence of carcinogenesis increased with
the addition of dysfunction of cancer-suppressing genes,
such as p53 and Ink4a/Arf. 17,25,26 When Cdh1-deficient
mice were subjected to mutational Kras activation (PKC
mice), histologic changes in the direction of tumor formation
were observed in the early postnatal stage, whereas Kras
activation alone resulted in no morphologic changes (PK
mice). This model showed the formation of PanIN and
increased stroma resembling aggressive tumors. In our
studies using td Tomato reporter mice, RFP-positive cells
were observed in the stroma. In addition, cells positive for
p-ERK and Ki67 were observed in the stroma, suggesting
the occurrence of massive neoplastic growth in the stroma.
The co-staining of RFP and CD44 indicates that those cells
have acquired tumorigenic activity.
E-cadherin is considered to act as a tumor suppressor,27
and mutation of its gene contributes to carcinogenesis. In
gastric and breast cancer, Cdh1 deficiency and mutation are
observed at a certain frequency.28,29 Low E-cadherin
expression level has been reported in pancreatic cancer,7
but Cdh1 deficiency and mutation are uncommon.30 There-
fore, the role of E-cadherin in pancreatic cancer still is un-
clear. The mouse model produced in this study combined
the deficiency of E-cadherin and mutational Kras activation
in the pancreas. This model showed PanIN formation and
increased stroma resembling aggressive tumors at an early
stage after birth. Our studies using td Tomato and YFP re-
porter mice indicated the presence of cells derived from
Ptfla-Cre in the stroma,31,32 and cells positive for p-ERK and
Ki67 were observed in the stroma. These observations
suggest the occurrence of neoplastic growth. Because these
model mice die approximately 10 days after birth, evalua-
tion of the tumors themselves was difficult. Therefore, we
produced a tamoxifen-inducible mouse model. Mutational
Kras activation and Cdh1 deficiency were introduced in the
mature pancreas. This transgenic mouse model showed
PanIN formation, which takes half a year with Krasmutation
alone,17 within the entire pancreas at approximately 6
weeks of age.
The observations of the present study raise questions
as to why tumor formation occurs more quickly in the
E-cadherin deletion model. One possibility is that compen-
satory proliferation after cell death owing to E-cadherin
deletion may play an important role in transformed cell
proliferation. Previously, we reported that the death of
parenchymal cells activated adjacent myeloid cells to pro-
duce mitogens that promote compensatory proliferation of
surviving transformed parenchymal cells to liver carcino-
genesis.33 However, we saw only a small amount of cell
death in the model, whereas proliferative response and
mitogenic cytokine levels were increased. Alternatively,
deletion of E-cadherin may confer tumorigenic activity and
cause cellular reprogramming, resulting in tumor initia-
tion.34 Recent reports have suggested that the transient
expression of reprogramming factors in Kras mutant mice is
sufficient to induce the activation of ERK signaling in acinar
cells and rapid formation of PDAC.35 Notably, we found that
expression levels of Cd44, Klf4, Klf5, and Cd133, markers of
stem cells or reprogramming, were increased in PKC tumor
tissues. High Cd44 expression level is correlated with poor
prognosis and poorly differentiated phenotype in human
PDAC.36–38 Klf4 and Klf5 also are expressed in pancreatic
cancer and have been reported to be an important tran-
scription factor for PanIN formation.39,40 The increased
mRNA level of c-Myc in iKrasG12D/þ; Cdh1f/f pancreatic tissue
indicates promotion of Wnt-induced growth signaling
pathways. In the organoids of the PKC mice, b-catenin was
transferred to the cytoplasm and the mRNA levels of c-Myc,
Axin1, and Lef1, which are markers of Wnt signaling, were
increased in comparison with those of the PKCþC mice.
Structurally, E-cadherin and b-catenin are connected, and it
is thought that Wnt signaling is activated by b-catenin in the
absence of E-cadherin.2 However, the precise mechanism by
which deletion of E-cadherin increases the expression of
these factors is unknown.
Another question is whether E-cadherin deletion in tu-
mors causes EMT or a histologically undifferentiated pheno-
type. In gastric cancer and breast cancer, Cdh1-deficient
tumors often become poorly differentiated tissue.8,41 In the
present study, allografts of Cdh1-deficient and Kras muta-
tional tumors showed a tissue type similar to undifferentiated
pancreatic cancer. E-cadherin–deficient tumor cells were
positive for vimentin and showed high motility and inva-
siveness, suggesting that the cells had gained an EMT
phenotype. However, we did not see an apparent increase in
metastasis associated with E-cadherin deletion. These ob-
servations were consistent with a previous report that EMT
may increase tumor invasiveness, but are not involved in
tumor metastasis in vivo.42
Although it is difficult to capture the target of a candidate
treatment for tumors in E-cadherin deletion or reduced
tumors, the results of our cDNA microarray analysis indi-
cated that Hdac1 was one of the targets. HDAC plays an
important role in chromatin remodeling and controls tran-
scription. The expression of HDAC is increased in tumors
and suppresses the expression of tumor-suppressor genes
by epigenetic control to deacetylate histones and therefore
promotes tumor formation. HDAC inhibitor was reported to
up-regulate a gene, the expression of which is suppressed by
histone acetylation.43 In pancreatic cancer, HDAC is
increased and it has been reported that HDAC increase in-
hibits the expression of E-cadherin.44 There have been no
reports of increased HDAC expression resulting from the
loss of E-cadherin in the pancreas and, therefore, further
studies are required. We examined whether the presence or
absence of E-cadherin in pancreatic cancer cells contributes
to the effect of HDAC inhibition using an HDAC inhibitor,
which already has been introduced in a clinical trial in
pancreatic cancer.45 The results indicated that Cdh1
knockout cells had more aggressive proliferative behavior,
but the inhibition rate by HDAC inhibitor was greater than
that in the presence of Cdh1, and so loss of E-cadherin may
be a predictive marker for the effectiveness of HDAC in-
hibitor treatment. In clinical trials, HDAC inhibitors have not
been used in combination with key drugs such as gemcita-
bine, and so further trials are warranted. In addition,
although the effect of HDAC inhibitors on E-cadherin
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deficiency has been reported, the presence of a variety of
genetic mutations reduces their efficacy in clinical prac-
tice.44 In this study, we used a model in which E-cadherin
was deleted and Kras was mutated, and so the effect of the
HDAC inhibitor may have resulted from the lower grade of
malignancy compared with human pancreatic cancer.
In summary, E-cadherin is important for maintenance of
homeostasis in the pancreas. Under pathologic conditions
with mutational Kras activation, E-cadherin plays an
important role in tumor formation via acquisition of
tumorigenic activity. Loss of E-cadherin is associated with
an increase in Hdac1 expression, and Cdh1-negative patients
may show a greater beneficial effect of HDAC inhibitor
treatment.
Materials and Methods
Mice
Ptf1a-Cre, LSL-KrasG12D/þ, Ptf1a-CreERT, Cdh1f/f, and
Rosa26-LSL-tdTomato mice were described
previously.17,21,31,46,47 Nude mice were purchased from
CLEA (Tokyo, Japan). The mice were maintained at the
Institute for Adult Diseases of the Asahi Life Foundation and
the Graduate School of Medicine of Yokohama City Univer-
sity. The Ethics Committees for Animal Experimentation of
Yokohama City University and the Institute for Adult Dis-
eases of the Asahi Life Foundation approved all experiments
involving animals.
Organoid Experiments
Isolated pancreatic tissue was minced and digested in
dissociation medium consisting of Dulbecco’s modified Ea-
gle medium (DMEM) supplemented with 1% fetal bovine
serum and 5 mg/mL collagenase II (Sigma, St. Louis, MO).
Next, pancreatic tissue was mixed with Matrigel (Corning)
and seeded onto plates containing culture medium con-
sisting of Advanced DMEM/F12 (Gibco, Waltham, MA)
supplemented with 10 mmol/L 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid, B27, and N2, 10 mmol/L
nicotinamide, 1 mmol/L N-acetylcysteine (Sigma), 50 ng/mL
epidermal growth factor (Peprotech), 100 ng/mL fibroblast
growth factor (Peprotech), 100 ng/mL Noggin (Peprotech,
Rocky Hill, NJ), 10% R-spondin-1–conditioned medium, and
50% Wnt3A conditioned medium. The organoids were
incubated in Cell Recovery Solution (BD Biosciences,
Franklin Lakes, NJ) and embedded in Matrigel to be
passaged.
To induce Cre recombination, organoids were infected
with Cre-expressing lentiviral vectors and selected using
puromycin. In addition, Cdh1-deleted organoids were
infected with lenti-Cdh1 to induce re-expression of CDH1,
and were selected using hygromycin B.
Reagents
The HDAC inhibitor (SAHA, cat 10009929; Cayman
Chemical, Ann Arbor, MI) was dissolved in dimethyl sulf-
oxide at 100 mmol/L and diluted to 1 mmol/L. The primary
antibodies used in these experiments were anti–E-cadherin,
anticleaved caspase-3, anti–phospho-ERK, anti-gH2AX, and
antivimentin (Cell Signaling, Beverly, MA); anti-Ki67, anti-
amylase, and anti-CK19 (Abcam); anti–a-SMA (Santa Cruz
Biotechnology, Santa Cruz, CA); anti-CD45 and anti–b-cat-
enin (BD Biosciences); anti-RFP (Rockland Antibodies &
Assays, Limerick, PA); and anti–green fluorescent protein
(Medical & Biological Laboratories, Nagoya, Japan). Tamox-
ifen (Sigma) was dissolved in corn oil containing 10%
ethanol and was administered by oral gavage to mice at 6
weeks of age (5 mg per mouse).
Histology
The pancreas was isolated from the mice and fixed in
10% formalin in phosphate buffer. Tissues were embedded
in paraffin, cut into sections, mounted on slides, and sub-
jected to staining with H&E or PSR, and processed for IHC.
After deparaffinization and rehydration, the slides were
incubated with 3% H2O2 at room temperature to block
endogenous peroxidase activity. For antigen retrieval, the
slides were incubated for 15 minutes at 121"C in an auto-
clave or twice for 10 minutes each in a microwave oven at
600 W, and subsequently incubated overnight at 4"C with
the indicated primary antibodies. Biotinylated anti-rabbit,
anti-rat, and anti-mouse secondary antibodies (1:200 dilu-
tion; Vector Laboratories, Burlingame, CA) were next added
for 30 minutes at room temperature. The solutions in the
Vectastain ABC Kit (Vector Laboratories) diluted 1:200 were
applied to the slides in accordance with the manufacturer’s
directions. After 30 minutes, the slides were developed with
3,30-diaminobenzidine substrate (Muto Pure Chemicals,
Tokyo, Japan) and counterstained with hematoxylin. The
area of staining was quantitated using ImageJ software
(National Institutes of Health, Bethesda, MD). For immuno-
fluorescence, slides were incubated with the indicated pri-
mary antibodies, followed by the corresponding secondary
antibodies labeled with Alexa 488 or 594 (Molecular Probes,
Eugene, OR). After 30 minutes, the slides were mounted
with 4’,6-diamidino-2-phenylindole (Vector Laboratories).
Western Blot
Whole-pancreas protein homogenates and cell lysates
prepared using Tissue Protein Extraction Reagent (Thermo
Fisher Scientific) were subjected to sodium dodecyl
sulfate–polyacrylamide gel electrophoresis and transferred
onto Immobilon-P membranes (Merck Millipore). The
membranes were incubated in polyvinylidene difluoride
blocking reagent (Toyobo) for 1 hour and subsequently
overnight at 4"C with the indicated primary antibodies.
Next, the membranes were incubated with the appropriate
secondary antibodies, and immune complexes were detec-
ted using the ECL Prime Western Blotting Detection Reagent
(GE Healthcare). Images were obtained using an LAS-3000
(Fujifilm) or ChemiDoc (Bio-Rad) imaging system.
Quantitative Reverse-Transcription PCR
RNA was extracted from pancreatic tissue using ISO-
GEN2 (Nippon Gene, Tokyo, Japan), and cDNA was gener-
ated using a High-Capacity RNA-to-cDNA Kit (Thermo Fisher
116 Kaneta et al Cellular and Molecular Gastroenterology and Hepatology Vol. 9, No. 1
Scientific). Quantitative reverse-transcription PCR was per-
formed using Fast SYBR Green Master Mix (Thermo Fisher
Scientific) and a 7900HT Fast Real-Time PCR System
(Applied Biosystems, Foster City, CA). Gene expression
levels were normalized to that of GAPDH as an internal
reference. Primer sequences are available upon request.
Cell Culture
We established Ptf1acre/þ; KrasG12D/þ; Cdh1f/f (PKC) and
Ptf1acre/þ; KrasG12D/þ, re-expressing Cdh1 (PKCþC) 2D cell
lines from the organoids using the lentiviral vectors
described earlier in DMEM (Gibco) containing 10% fetal
bovine serum (Biosera, Nuaille, France), and 2% penicillin-
streptomycin (Thermo Fisher Scientific). Ptf1acre/þ; Cdh1f/f
organoids could not be established in 2D culture.
Subcutaneous Tumor and Liver Metastasis
Allograft Models
For the allograft model, centrifuged organoid frag-
ments were injected subcutaneously into nude mice. Tu-
mors were removed and measured when they became
palpable. For the liver metastasis model, we prepared 2D-
cultured cells from the organoids. The prepared cells were
injected into the spleen using a 29-gauge needle. To
prevent tumor-cell leakage, a cotton swab was held over
the spleen for 1 minute. The splenic blood vessels were
ligated, the injected spleen was removed, and the wound
was sutured with clips.
Wound Healing Assay
Mouse cancer cells were seeded onto 6-well plates and
starved of serum overnight when near complete confluence.
Next, scratch wounds (500 mm) were made using a cover
glass. The cells were incubated for up to 6 days and
migration was assessed at the indicated time points.
Invasion Assay
Invasion was assayed using a commercial kit (BioCoat
Matrigel Invasion Chamber; BD Biosciences), which contains
polyethylene terephthalate membrane inserts with a pore
size of 8.0 mm in a 24-well format, according to the manu-
facturer’s protocol.
Cell Proliferation Assay
Aliquots of 6 # 103 PKC or PKCþC cells were seeded
onto 48-well plates and incubated for 24 hours. The culture
medium was removed and fresh medium containing
dimethyl sulfoxide or SAHA was added. Next, 10 mL of Cell
Counting Kit-8 (Dojindo, Tokyo, Japan) solution was added
to each well and the culture medium was transferred to 96-
well plates for measurement of the absorbance at 450 nm
using a microplate reader (Beckman Coulter, Brea, CA) at 0,
12, 24, and 48 hours.
Microarray
The SurePrint G3 Mouse Gene Expression 8 # 60K v2
(Agilent Technologies, Santa Clara, CA) microarray was
used in this study according to the manufacturer’s pro-
tocol. The microarray data were subjected to gene set
enrichment analysis with permutations across gene sets
using the c5.all.v6.2.symbols.gmt gene sets from the Mo-
lecular Signatures Database.
Statistical Analysis
Values are presented as means ± SEM. The significance
of differences was examined using the Student t test. In all
analyses, P < .05 indicated statistical significance.
References
1. Takeichi M. Dynamic contacts: rearranging adherens
junctions to drive epithelial remodelling. Nat Rev Mol Cell
Biol 2014;15:397–410.
2. Halbleib JM, Nelson WJ. Cadherins in development: cell
adhesion, sorting, and tissue morphogenesis. Genes
Dev 2006;20:3199–3214.
3. Larue L, Ohsugi M, Hirchenhain J, Rolf Kemler.
E-cadherin null mutant embryos fail to form a tro-
phectoderm epithelium. Proc Natl Acad Sci U S A
1994;91:8263–8267.
4. Nakagawa H, Hikiba Y, Hirata Y, Font-Burgada J,
Sakamoto K, Hayakawa Y, Taniguchi K, Umemura A,
Kinoshita H, Sakitani K, Nishikawa Y, Hirano K,
Ikenoue T, Ijichi H, Debanjan D, Shibata W, Akanuma M,
Koike K, Karin M, Maeda S. Loss of liver E-cadherin in-
duces sclerosing cholangitis and promotes carcinogen-
esis. Proc Natl Acad Sci U S A 2014;111:1090–1095.
5. Nakada S, Tsuneyama K, Kato I, Tabuchi Y, Takasaki I,
Furusawa Y, Kawaguchi H, Fujimoto M, Goto H,
Hikiami H, Kondo T, Takano Y, Shimada Y. Identification
of candidate genes involved in endogenous protection
mechanisms against acute pancreatitis in mice. Biochem
Biophys Res Commun 2010;391:1342–1347.
6. Lerch MM, Lutz MP, Weidernbach H, Pillasch FM,
Gress TM, Leser J, Adler G. Dissociation and reassembly
of adherens junctions during experimental acute
pancreatitis. Gastroenterology 1997;113:1355–1366.
7. Deng S, Zhu S, Wang B, Li X, Liu Y, Qin Q, Gong Q,
Niu Y, Xiang C, Chen J, Jin Y, Deng S, Yin T, Yang M,
Wu H, Wang C, Zhao G. Chronic pancreatitis and
pancreatic cancer demonstrate active epithelial-
mesenchymal transition profile, regulated by miR-217-
SIRT1 pathway. Cancer Lett 2014;355:184–191.
8. Becker KF, Atkinson MJ, Reich U, Becker I, Nekarda H,
Siewert JR, Hofler H. E-cadherin gene mutations provide
clues to diffuse type gastric carcinomas. Cancer Res
1994;54:3845–3852.
9. Oliveira C, Pinheiro H, Figueiredo J, Seruca R,
Carneiro F. Familial gastric cancer: genetic susceptibility,
pathology, and implications for management. Lancet
Oncol 2015;16:e60–e70.
10. Hayakawa Y, Ariyama H, Stancikova J, Sakitani K,
Asfaha S, Renz BW, Dubeykovskaya ZA, Shibata W,
Wang H, Westphalen CB, Chen X, Takemoto Y, Kim W,
Khurana SS, Tailor Y, Nagar K, Tomita H, Hara A,
Seplveda AR, Setlik W, Gershon MD, Saha S, Ding L,
Shen Z, Fox JG, Friedman RA, Konieczny SF,
2020 Loss of Roles of E-Cadherin in the Pancreas 117
Worthley DL, Korinek V, Wang TC. Mist1 expressing
gastric stem cells maintain the normal and neoplastic
gastric epithelium and are supported by a perivascular
stem cell niche. Cancer Cell 2015;28:800–814.
11. Kinoshita H, Hayakawa Y, Konishi M, Hara M, Tsuboi M,
Hayata Y, Hikiba Y, Ihara S, Nakagawa H, Ikenoue T,
Ushiku T, Fukuyama M, Hirata Y, Koike K. Three types of
metaplasia models through Kras activation, Pten dele-
tion, or Cdh1 deletion in the gastric epithelium. J Pathol
2019;247:35–47.
12. Shimada S, Mimata A, Sekine M, Mogushi K, Akiyama Y,
Fukamichi H, Jonkers J, Tanaka H, Eishi Y, Yuasa Y.
Synergistic tumour suppressor activity of E-cadherin and
p53 in a conditional mouse model for metastatic diffuse-
type gastric cancer. Gut 2012;61:344–353.
13. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017.
CA Cancer J Clin 2017;67:7–30.
14. Chen L, Ma C, Bian Y, Shao C, Wang T, Li J, Chong X,
Su L, Lu J. Aberrant expression of STYK1 and E-cad-
herin confer a poor prognosis for pancreatic cancer pa-
tients. Oncotarget 2017;8:111333–111345.
15. Lee JM, Dedhar S, Kalluri R, Thompson EW. The
epithelial-mesenchymal transition: new insights in
signaling, development, and disease. J Cell Biol 2006;
172:973–981.
16. Rozenblum E, Schutte M, Goggins M, Hahn SA,
Panzer S, Zahurak M, Goodman SN, Sohn TA,
Hruban RH, Yeo CJ, Kern SE. Tumor-suppressive
pathways in pancreatic carcinoma. Cancer Res 1997;
57:1731–1734.
17. Hingorani SR, Petricoin EF, Maitra A, Rajapakse V,
King C, Jacobetz MA, Ross S, Conrads TP, Veenstra TD,
Hitt BA, Kawaguchi Y, Johann D, Liotta LA,
Crawford HC, Putt ME, Jacks T, Wright CVE, Hruban RH,
Lowy AM, Tuveson DA. Preinvasive and invasive ductal
pancreatic cancer and its early detection in the mouse.
Cancer Cell 2003;4:437–450.
18. Shibata W, Kinoshita H, Hikiba Y, Sato T, Ishii Y, Sue S,
Sugimori M, Suzuki N, Sakitani K, Ijichi H, Mori R, Endo I,
Maeda S. Overexpression of HER2 in the pancreas
promotes development of intraductal papillary mucinous
neoplasms in mice. Sci Rep 2018;8:6150.
19. Wang M, Han J, Marcar L, Black J, Liu Q, Li X,
Nagulapalli K, Sequist LV, Mak RH, Benes CH, Hong TS,
Gurtner K, Krause M, Baumann M, Kang JX,
Whetstine JR, Willers H. Radiation resistance in KRAS-
mutated lung cancer is enabled by stem-like properties
mediated by an osteopontin-EGFR pathway. Cancer Res
2017;77:2018–2028.
20. Cai MH, Xu XG, Yan SL, Sun Z, Ying Y, Wang BK, Tu YX.
Depletion of HDAC1, 7 and 8 by histone deacetylase inhi-
bition confers elimination of pancreatic cancer stemcells in
combination with gemcitabine. Sci Rep 2018;8:1621.
21. Serrill JD, Sander M, Shih HP. Pancreatic exocrine tissue
architecture and integrity are maintained by E-cadherin
during postnatal development. Sci Rep 2018;8:13451.
22. Tinkle CL, Lechler T, Pasolli HA, Fuchs E. Conditional
targeting of E-cadherin in skin: insights into hyper-
proliferative and degenerative responses. Proc Natl Acad
Sci U S A 2004;101:552–557.
23. Derksen PW, Liu X, Saridin F, van der Gulden H,
Zevenhoven J, Evers B, van Beijnum JR,
Griffioen AW, Vink J, Krimpenfort, Peterse JL,
Cardiff RD, Berns A, Jonkers J. Somatic inactivation
of E-cadherin and p53 in mice leads to metastatic
lobular mammary carcinoma through induction of
anoikis resistance and angiogenesis. Cancer Cell
2006;10:437–449.
24. Herreros-Villanueva M, Hijona E, Cosme A, Bujanda L.
Mouse models of pancreatic cancer. World J Gastro-
enterol 2012;18:1286–1294.
25. Hingorani SR, Wang L, Multani AS, Combs C,
Deramaudt TB, Hruban RH, Rustgi AK, Chang S,
Tuveson DA. Trp53R172H and KrasG12D cooperate to
promote chromosomal instability and widely metastatic
pancreatic ductal adenocarcinoma in mice. Cancer Cell
2005;7:469–483.
26. Aguirre AJ, Bardeesy N, Sinha M, Lopez L, Tuveson DA,
Horner J, Redston MS, DePinho RA. Activated Kras and
Ink4a/Arf deficiency cooperate to produce metastatic
pancreatic ductal adenocarcinoma. Genes Dev 2003;
17:3112–3126.
27. Jeanes A, Gottardi CJ, Yap AS. Cadherins and cancer:
how does cadherin dysfunction promote tumor pro-
gression? Oncogene 2008;27:6920–6929.
28. Corso G, Carvalho J, Marrelli D, Vindigni C, Carvalho B,
Seruca R, Roviello F, Oliveira C. Somatic mutations and
deletions of the E-cadherin gene predict poor survival of
patients with gastric cancer. J Clin Oncol 2013;
31:868–875.
29. Stuebs F, Heidemann S, Caliebe A, Mundhenke C,
Arnold N. CDH1 mutation screen in a BRCA1/2-negative
familial breast-/ovarian cancer cohort. Arch Gynecol
Obstet 2018;297:147–152.
30. Busch EL, Hornick JL, Umeton R, Albayrak A,
Lindeman NI, MacConail LE, Garcia EP, Ducar M,
Rebbeck TR. Somatic mutations in CDH1 and CTNNB1
in primary carcinomas at 13 anatomic sites. Oncotarget
2017;8:85680–85691.
31. Madisen L, Zwingman TA, Sunkin SM, Oh SW,
Zariwala HA, Gu H, Ng LL, Palmiter RD, Hawrylycz MJ,
Jones AR, Lein ES, Zeng H. A robust and high-
throughput Cre reporting and characterization system
for the whole mouse brain. Nat Neurosci 2010;
13:133–140.
32. Nagai T, Ibata K, Park ES, Kubota M, Mikoshiba K,
Miyazaki A. A variant of yellow fluorescent protein with
fast and efficient maturation for cell-biological applica-
tions. Nat Biotechnol 2002;20:87–90.
33. Maeda S, Kamata H, Luo JL, Leffert H, Karin M. IKKbeta
couples hepatocyte death to cytokine-driven compen-
satory proliferation that promotes chemical hep-
atocarcinogenesis. Cell 2005;121:977–990.
34. Skrypek N, Goossens S, De Smedt E, Vandamme N,
Berx G. Epithelial-to-mesenchymal transition: epigenetic
reprogramming driving cellular plasticity. Trends Genet
2017;33:943–959.
35. Shibata H, Komura S, Yamada Y, Sankoda N, Tanaka A,
Ukai T, Kabata M, Sakurai S, Kuze B, Woltjen K, Haga H,
Ito Y, Kawaguchi Y, Yamamoto T, Yamada Y. In vivo
118 Kaneta et al Cellular and Molecular Gastroenterology and Hepatology Vol. 9, No. 1
reprogramming drives Kras-induced cancer develop-
ment. Nat Commun 2018;9:2081.
36. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A,
Zhou AY, Brooks M, Reinhard F, Zhang CC,
Shipitsin Campbell LL, Polyak K, Brisken C, Yang J,
Weinberg RA. The epithelial-mesenchymal transition
generates cells with properties of stem cells. Cell 2018;
133:704–715.
37. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW,
Guba M, Bruns CJ, Heeschen C. Distinct populations of
cancer stem cells determine tumor growth and meta-
static activity in human pancreatic cancer. Cell Stem Cell
2007;1:313–323.
38. Li XP, Zhang XW, Zheng LZ, Guo WJ. Expression of
CD44 in pancreatic cancer and its significance. Int J Clin
Exp Pathol 2015;8:6724–6731.
39. Wei D, Wang L, Yan Y, Jia Z, Gagea M, Li Z, Zuo X,
Kong X, Huang S, Xie K. KLF4 is essential for induction
of cellular identity change and acinar-to-ductal reprog-
ramming during early pancreatic carcinogenesis. Cancer
Cell 2016;29:324–338.
40. He P, Yang JW, Yang VW, Bialkowska AB. Kruppel-like
factor 5, increased in pancreatic ductal adenocarcinoma,
promotes proliferation, acinar-to-ductal metaplasia,
pancreatic intraepithelial neoplasia, and tumor growth in
mice. Gastroenterology 2018;154:1494–1508 e13.
41. Orlandini LF, Reis F, da Silveira WA, Tiezzi MG, de
Andrade JM, Silva AR, Deaton R, Bosland M, Tizzi DG.
Identification of a subtype of poorly differentiated inva-
sive ductal carcinoma of the breast based on vimentin
and E-cadherin expression. Rev Bras Ginecol Obstet
2018;40:779–786.
42. Zheng X, Carstens JL, Kim J, Matthew Scheible, Kaye J,
Sugimoto H, Wu CC, LeBleu VS, Kalluri R. Epithelial-to-
mesenchymal transition is dispensable for metastasis
but induces chemoresistance in pancreatic cancer. Na-
ture 2015;527:525–530.
43. Ozaki K, Kishikawa F, Tanaka M, Sakamoto T,
Tanimura S, Kohno. Histone deacetylase inhibitors
enhance the chemosensitivity of tumor cells with cross-
resistance to a wide range of DNA-damaging drugs.
Cancer Sci 2008;99:376–384.
44. Aghdassi A, Sendler M, Guenther A, Mayerle J, Behn CO,
Heiecke CD, Friess H, Buchler, Evert M, Lerch MM,
Weiss FU. Recruitment of histone deacetylases HDAC1
and HDAC2 by the transcriptional repressor ZEB1
downregulates E-cadherin expression in pancreatic
cancer. Gut 2012;61:439–448.
45. Chan E, Arlinghaus LR, Cardin DB, Goff L, Berlin JD,
Parikh A, Abramson RG, Yankeelov TE, Hiebert S,
Merchant N, Bhaskara S, Chakravarthy AB. Phase I trial of
vorinostat added to chemoradiation with capecitabine in
pancreatic cancer. Radiother Oncol 2016;119:312–318.
46. Pan FC, Bankaitis ED, Boyer D, Xu X, Van de Casteele M,
Magnuson MA, Heimberg H, Wright CVE. Spatiotem-
poral patterns of multipotentiality in Ptf1a-expressing
cells during pancreas organogenesis and injury-
induced facultative restoration. Development 2013;
140:751–764.
47. Kopinke D, Brailsford M, Pan FC, Magnuson MA,
Wright XVE, Murtaugh LC. Ongoing Notch signaling
maintains phenotypic fidelity in the adult exocrine
pancreas. Dev Biol 2012;362:57–64.
Received March 5, 2019. Accepted September 9, 2019.
Correspondence
Address correspondence to: Shin Maeda, MD, PhD Department of
Gastroenterology, Graduate School of Medicine Yokohama City University,
3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan. e-mail:
smaeda@yokohama-cu.ac.jp; fax: (81) 45-787-2327.
Acknowledgments
The authors thank Yuki Yamashita for technical assistance. We cited the
mouse image with permission from the Database Center for Life Science
(Japan) (2016 DBCLS TogoTV).
Author contributions
Yoshihiro Kaneta, Takeshi Sato, Yohko Hikiba, Makoto Sugimori, Soichiro Sue,
Hiroaki Kaneko, Kuniyasu Irie, Tomohiko Sasaki, and Masaaki Kondo
performed the research; Wataru Shibata and Makoto Chuma designed and
performed the research; and Shin Maeda designed and wrote the manuscript.
Conflicts of interest
The authors disclose no conflicts.
Funding
This work was supported by the Japan Society for the Promotion of Science
KAKENHI grant JP17K09465 and the Yokohama City University Kamome
project.
2020 Loss of Roles of E-Cadherin in the Pancreas 119
 
Ħ¾÷Ķ 
 
aĦ¾Ł 
Kaneta Y, Sato T, Hikiba Y, Sugimori M, Sue S, Kaneko H, Irie K, Sasaki T, Kondo M, 
Chuma M, Shibata W, Maeda S. (2019), Loss of Pancreatic E-Cadherin Causes 
Pancreatitis-Like Changes and Contributes to Carcinogenesis, Cell Mol Gastroenterol 
Hepatol, 14, 9, 1, 105-119. 
 
